Back to top
more

KORU Medical Systems, Inc. (KRMD)

(Delayed Data from NSDQ)

$3.38 USD

3.38
101,644

-0.10 (-2.87%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Omnicell (OMCL) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of +45.16% and +4.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -50% and 6.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integer (ITGR) Soars 3.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Integer (ITGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does KORU Medical Systems Inc. (KRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 6.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of 20% and 4.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -25.53% and 0.83%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 0% and 3.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Teleflex (TFX) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 3.25% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 26.76% and 6.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 12.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 1,100% and 14.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

DexCom (DXCM) Q2 Earnings Surpass Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 10.26% and 3.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan

by Zacks Equity Research

KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 9.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion

by Zacks Equity Research

One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.

Zacks Equity Research

Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Silk Road Medical (SILK) delivered earnings and revenue surprises of 17.50% and 11.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 0.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo (MASI) Q2 Earnings Miss Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of -27.91% and 0.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 53.57% and 3.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -25% and 1%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.